The Advisory Committee on Immunization Practices (ACIP) makes shared clinical decision-making recommendations when individuals may benefit from vaccination, but broad vaccination of all people in that group is unlikely to have population-level impact. Such a recommendation is applicable to pneumococcal vaccines whereby pneumococcal conjugate vaccine (PCV13) is recommended for all adults 65 and older, while the administration of pneumococcal conjugate vaccine (PCV13) is based on shared decision-making. In this podcast, we will discuss the ACIP recommendations and the use of shared decision-making as it applies to pneumococcal vaccines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/18/2020 and they are subject to change as new information is published.
Adults between the ages of 18 through 64 with immunocompromising conditions due to either anatomic defects or impaired immune response are at the highest risk for invasive pneumococcal disease. They need two different pneumococcal vaccines: pneumococcal conjugate vaccine (PCV13) at the time the risk factor is recognized and pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks later. This podcast will discuss how to identify these patients at high risk for pneumococcal disease and implement guidelines for administration of pneumococcal vaccination in this population. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/18/2020 and they are subject to change as new information is published.
Most patients between ages 18 and 64 presenting to primary care practices have a comorbidity that increases their risk for invasive pneumococcal disease and thus warrants immunization. These comorbidities include diabetes, cardiovascular disease, respiratory disease (such as asthma or COPD), liver disease, smoking, and others. This podcast will discuss the recommendations for pneumococcal vaccines in this population.